Cetuximab, an anti-EGFR antibody used for cancer therapy, was reported to be able to sensitize human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α (33). This evidence concerns the gene HIF1A and head and neck squamous cell carcinoma.